Invion (ASX:INV)

Executive Summary

Invion is an Australian clinical-stage life sciences company pioneering the Photosoft™ photodynamic therapy (PDT) platform. Photosoft leverages proprietary photosensitizers to generate targeted reactive oxygen species upon light activation, enabling minimally invasive treatment of a broad range of diseases. The company's lead programs focus on oncology, including skin and solid tumors, as well as infectious diseases, dental/periodontal conditions, and ophthalmology. By delivering precision therapy with reduced side effects compared to conventional modalities, Invion aims to address significant unmet medical needs. The company is publicly traded on the ASX (INV) and maintains a focused R&D strategy to advance its pipeline through preclinical and early clinical stages. Invion has successfully completed initial preclinical studies demonstrating the Photosoft platform's potential across multiple indications. The company is currently advancing its lead candidate toward Phase 1 clinical trials, with an emphasis on establishing safety and preliminary efficacy. Key upcoming milestones include the initiation of Phase 1 studies for a solid tumor indication and continued development of its PDT platform for infectious and inflammatory diseases. While still in early stages, Invion's technology has garnered interest for its versatility and potential to disrupt traditional treatment paradigms. The company's success hinges on clinical validation, regulatory progress, and securing partnerships to accelerate development.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 Clinical Trial Initiation for Solid Tumor Indication70% success
• Q4 2026Preclinical Data Readout for Infectious Disease Application65% success
• TBDPotential Licensing or Partnership Agreement for Photosoft Platform40% success